|
Index | - | P/E | - | EPS (ttm) | -2.81 | Insider Own | - | Shs Outstand | 15.60M | Perf Week | 1.39% |
Market Cap | 124.93M | Forward P/E | - | EPS next Y | -2.21 | Insider Trans | - | Shs Float | 3.99M | Perf Month | -1.23% |
Income | - | PEG | - | EPS next Q | -0.47 | Inst Own | 20.55% | Short Float | 0.09% | Perf Quarter | 0.13% |
Sales | 22.24M | P/S | 5.62 | EPS this Y | - | Inst Trans | - | Short Ratio | 0.06 | Perf Half Y | -15.86% |
Book/sh | 1.81 | P/B | 4.43 | EPS next Y | 1.80% | ROA | - | Target Price | 15.33 | Perf Year | - |
Cash/sh | - | P/C | - | EPS next 5Y | - | ROE | - | 52W Range | 6.20 - 13.17 | Perf YTD | -15.86% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -41.46% | Beta | - |
Dividend % | - | Quick Ratio | - | Sales past 5Y | - | Gross Margin | - | 52W Low | 24.35% | ATR | 0.61 |
Employees | - | Current Ratio | - | Sales Q/Q | 34.10% | Oper. Margin | - | RSI (14) | 49.93 | Volatility | 7.34% 6.25% |
Optionable | No | Debt/Eq | - | EPS Q/Q | - | Profit Margin | - | Rel Volume | 0.01 | Prev Close | 8.01 |
Shortable | Yes | LT Debt/Eq | - | Earnings | - | Payout | - | Avg Volume | 57.39K | Price | 7.71 |
Recom | 1.30 | SMA20 | 2.04% | SMA50 | -0.28% | SMA200 | -10.18% | Volume | 134 | Change | -3.75% |
![]() |
|
![]() | ||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium. | ||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||
![]() |
open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite